This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Efficacy Registry of Yinyi Stent (SERY-I)

This study has been completed.
Information provided by:
Shanghai Jiao Tong University School of Medicine Identifier:
First received: April 1, 2011
Last updated: July 27, 2015
Last verified: October 2008
Drug-eluting stents effectively reduce restenosis but may increase late thrombosis and delayed restenosis. Persistent polymer could be responsible. Local delivery of paclitxel from a polymer-free Yinyi stent (Dalian Yinyi biomaterial research and development may prevent these complications.

Condition Intervention Phase
Coronary Artery Disease Device: Yinyi stent Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety and Efficacy Registry of Yinyi Polymer-free Paclitaxel-eluting Stent

Further study details as provided by Shanghai Jiao Tong University School of Medicine:

Primary Outcome Measures:
  • major adverse cardiac events [ Time Frame: 12 months ]
    including cardiac death, myocardial infarction and target vessel failure

Secondary Outcome Measures:
  • stent thrombosis [ Time Frame: 12 months ]
    according to ARC definition

Enrollment: 1045
Study Start Date: January 2009
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Yinyi stent
subjects with Yinyi stent implantation
Device: Yinyi stent
subjects with Yinyi stent implantation


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • age 18-80 years old
  • both gender
  • native coronary lesion
  • narrowing > 70%
  • vessel size 2.5-4.0 in diameter

Exclusion Criteria:

  • without informed consent,
  • ST elevation myocardial infarction within 7 days,
  • patient with ≤ 70% coronary narrowing at target lesion,
  • left main lesion,
  • multivessel narrowing need more than 3 stent implantations,
  • by-pass graft,
  • abnormal liver function before randomization,
  • active hepatitis or muscular disease,
  • impaired renal function with serum creatinine level > 3mg/dl,
  • impaired left ventricular function with LVEF < 30%,
  • Participate in other studies.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01373645

China, Shanghai
ruijin hospital, Shanghai Jiao Tong University, School of Medicine
Shanghai, Shanghai, China, 200025
Sponsors and Collaborators
Shanghai Jiao Tong University School of Medicine
  More Information

Responsible Party: Weifeng Shen, Ruijin hospital, shanghai jiao tong university school of medicine Identifier: NCT01373645     History of Changes
Other Study ID Numbers: RJH20100909
Study First Received: April 1, 2011
Last Updated: July 27, 2015

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases processed this record on September 21, 2017